---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-130516"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2023-12-29T23:59:59+00:00"
generated_at: "2026-06-07T05:48:23.190073+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immunome CFO Corleen Roche departs; Max Rosett named Interim CFO; Bob Lapetina named principal accounting officer

## Summary
- CFO Corleen Roche separates effective Jan 2, 2024; receives 10.5 months salary continuation, $75,000 cash, COBRA coverage, and one-year option exercise extension.
- Roche to provide consulting from Jan 2 to Apr 5, 2024 at $300/hour; equity continues vesting during consulting period.
- Max Rosett appointed Interim CFO and principal financial officer; he has served as SVP Operations since Oct 2023.
- Bob Lapetina appointed principal accounting officer; is VP Finance & Corp Controller since May 2021; eligible for two $15,000 retention bonuses through 2024.

## SEC filing metadata
- accession: 0001104659-23-130516
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2023-12-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465923130516/0001104659-23-130516-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465923130516/tm2333682d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-130516
- JSON: https://secwatch.observer/filing/0001104659-23-130516.json
- Plain text: https://secwatch.observer/filing/0001104659-23-130516.txt

## Key facts
- Executive change
  Bob Lapetina was appointed as Principal Accounting Officer at Immunome Inc..
  - Action: appointed
  - Role: Principal Accounting Officer
  source text: appointed Bob Lapetina, in addition to his other titles, as the Company’s principal accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465923130516/0001104659-23-130516-index.htm
- Executive change
  Max Rosett was appointed as Interim Chief Financial Officer at Immunome Inc..
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: appointed Max Rosett, in addition to his other titles, as the Company’s Interim Chief Financial Officer and principal financial officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465923130516/0001104659-23-130516-index.htm
- Executive change
  Corleen Roche departed as Chief Financial Officer at Immunome Inc..
  - Action: agreed to a mutual separation
  - Role: Chief Financial Officer
  source text: Ms. Roche will no longer serve as the Company’s Chief Financial Officer, principal financial officer or principal accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465923130516/0001104659-23-130516-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.